ArticleWorld journal of surgical oncology2025
The PVT1-214/miR-671-5p/SLC45A4 signaling axis regulates cell proliferation in human gastric cancer.
Article in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Long non-coding RNA SOCS2-AS1 inhibits gastric cancer progression via the miR-324-3p/GRIK3 axis: a mechanistic study.World journal of surgical oncology · 2026Article
- Regulation of miR-27a-3p/FBXW7 axis by increasing the level of lncRNA AC138128.1 to mitigate gastric cancer progression.World journal of surgical oncology · 2026Article
- Sugar transporter SLC45 gene family members: roles in malignant tumors and research progress.Molecular biology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundLong non-coding RNA PVT1 (lncRNA PVT1) serves as a carcinogenic regulatory factor in several cancers; however, the expression and function of its transcriptional isomer PVT1-214 in gastric cancer (GC) are poorly understood.
methodsPVT1-214 and miR-671-5p levels in GC cells and tissues were analyzed through quantitative real-time polymerase chain reaction (qRT-PCR). Western blotting (WB) was used to detect Homo sapiens solute carrier family 45 member 4 (SLC45A4) expression in GC cells. Thereafter, the relationship between PVT1-214 and miR-671-5p was evaluated through dual-luciferase reporter assays and RNA immunoprecipitation (RIP) analysis. Additionally, the biological activities of PVT1-214, miR-671-5p and SLC45A4 in GC cells were analyzed through Cell Counting Kit-8 (CCK-8), 5-ethyl-20-deoxyuridine (EdU), colony formation and Transwell assays. The effect of PVT1-214 on GC was studied in vivo via a nude mouse tumor xenograft model.
resultsPVT1-214 overexpression in GC cells and tissues was positively related to tumor size, malignancy grade, lymphatic metastasis and clinical stage. PVT1-214 knockdown suppressed cell growth, invasion and migration in vitro, whereas PVT1-214 overexpression promoted tumor proliferation in vivo. In addition, PVT1-214 positively regulates SLC45A4 expression through its competitive endogenous RNA (ceRNA) activity against miR-671-5p. SLC45A4 expression was positively related to PVT1-214 expression. PVT1-214 competes with endogenous RNA (ceRNA) by binding to miR-671-5p. When miR-671-5p is inhibited, SLC45A4 is released from the complementary binding complex, thereby increasing SLC45A4 protein levels in GC cells.
conclusionsThe present work revealed the candidate ceRNA regulatory pathway by which PVT1-214 regulates SLC45A4 expression in GC cells, which is achieved through competitive binding to endogenous miR-671-5p. The results of this study can shed novel light on new molecular targets for treating GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.